Eloxx Pharmaceuticals, Inc. Balance Sheet
ELOX|4 years of annual SEC 10-K data (FY2014-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 4 fiscal years. All figures from audited SEC 10-K filings.
Eloxx Pharmaceuticals, Inc. had $2M in total assets with negative shareholders' equity of $11M as of FY2025. Total debt was $1M against $1M in cash, resulting in a $134,000 net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -40.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|
| Cash & Equivalents | $1.1M | $6.1M | $1.6M | $2.0M |
| Accounts Receivable | - | - | - | $43.1K |
| Current Assets | $1.5M | $982.6K | $3.7M | $7.2M |
| PP&E (Net) | $35.0K | $92.6K | $185.9K | $223.5K |
| Goodwill | - | $13.9M | $13.9M | $13.9M |
| Total Assets | $1.7M | $9.2M | $19.5M | $33.3M |
| Current Liabilities | $22.7M | $369.0K | $778.5K | $1.8M |
| Total Debt | $1.0M | - | - | - |
| Shareholders' Equity | -$10.7M | $27.5M | $3.8M | $3.5M |